UNSPSC 51413301: Alprostadil

This classification denotes a prostaglandin analogue with the molecular formula C20H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F5TD010360, chemically known as 11.alpha., 15.alpha.-dihydroxy-9-oxo-13-trans-prostenoic acid but generally known as alprostadil, which bears US NIH Compound Identifier 214. Alprostadil most often comes in alfadex and prostoglandinalfadex and prostoglandin forms.

UNSPSC 51413301 Alprostadil is a Commodity code covering specific pharmaceutical products supplied to state and local health-care and emergency-response agencies. Recent state and local solicitations under this code reflect procurement of advanced life support and emergency medications for fire rescue departments and pharmacy benefit programs. The City of Tampa's Fire Rescue Department procures emergency injectable medications including epinephrine, adenosine, labetalol, and diltiazem through sealed-bid IFBs; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models through an RFI; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicits generic multi-source pharmaceuticals and OTC products through RFPs to supply state and local government facilities across participating jurisdictions including Oregon. Issuing bodies are primarily municipal fire/rescue departments, state health agencies, and state cooperative purchasing entities procuring on behalf of multiple member jurisdictions. Vendors must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) attestation, and maintain expiration-date minimums (typically six months to one year from manufacture). Delivery timelines range from ten calendar days for emergency medications to coordinated distribution through authorized wholesalers by specified effective dates. Pricing models include firm fixed-price, net-price formats, and WAC-minus structures, with administrative fees (such as the 3 percent MMCAP fee) commonly deducted from contract revenues.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 in April 2026 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent SLBE bid discount not to exceed $10,000 and a one-year term with optional two-year renewals plus three unilateral 30-day extensions. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, sought vendor capabilities for direct-to-manufacturer prescription programs without specified award values or timelines. MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, targets generic multi-source pharmaceuticals for July 1, 2026 effectiveness across multi-state public health systems, with evaluation weighted 75 percent on price competitiveness and performance penalties of $200 to $1,500 per violation. These opportunities reflect demand from emergency medical, state pharmacy benefit, and cooperative purchasing channels serving multiple jurisdictions simultaneously.